federal_register: 2016-20778
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-20778 | Bioequivalence Recommendations for Risperidone; Draft Guidance for Industry; Availability | Notice | The Food and Drug Administration (FDA) is announcing the availability of a revised draft guidance for industry on generic risperidone injection, entitled "Bioequivalence Recommendations for Risperidone." The recommendations provide specific guidance on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for risperidone injection. | 2016-08-30 | 2016 | 8 | https://www.federalregister.gov/documents/2016/08/30/2016-20778/bioequivalence-recommendations-for-risperidone-draft-guidance-for-industry-availability | https://www.govinfo.gov/content/pkg/FR-2016-08-30/pdf/2016-20778.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA) is announcing the availability of a revised draft guidance for industry on generic risperidone injection, entitled "Bioequivalence Recommendations for Risperidone." The recommendations provide specific guidance on... |